美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ASTRAZENECA PLC ADRhedged

53.28

0.0000

成交量：- -

成交額：- -

市值：159.83萬

市盈率：- -

高：53.28

開：53.28

低：53.28

收：53.28

52周最高：56.90

52周最低：44.36

股本：3.00萬

流通股本：1.00萬

量比：- -

換手率：- -

股息：0.58

股息率：1.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

第3次更新-阿斯利康因暫停volrustomig肺癌臨床試驗再遭挫折

阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功

阿斯利康終止一項肺癌三期臨床試驗，稱療效難達主要終點

阿斯利康（AZN）再遇重大臨床研發挫折宣佈停止肺癌治療藥物Volrustomig三期試驗

阿斯利康（AZN）與日本第一三共聯合宣佈重磅抗體偶聯藥物Enhertu®三期臨床取得重大突破

泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇

阿斯利康(AZN.US)宣佈終止其實驗性藥物volrustomig的臨床試驗，此前數據顯示，該藥物似乎無法在肺癌治療方面

阿斯利康宣佈泰適卓在華上市

阿斯利康宣佈泰適卓正式在華上市

據美國財經媒體Semafor：英國首相顧問曾就阿斯利康與百時美施貴寶的合併事宜致電阿斯利康。

市場消息：英國首相顧問就布里斯托爾併購案聯繫阿斯利康。

第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市

康方生物雙抗藥物獲批第三項適應證此前擊敗百濟神州；阿斯利康加入口服減重藥「混戰」：4500人Ⅲ期臨床試驗只對標安慰劑｜掘金創新藥

每日经济新闻

石藥創新(300765.SZ)：巨石生物已收到阿斯利康支付的3000萬美元首付款

石藥創新：控股子公司收到阿斯利康3000萬美元首付款

優赫得聯合帕妥珠單抗在華獲批HER2陽性轉移性乳腺癌一線治療，成為十餘年來該領域首個獲批的創新ADC方案

數據簡報-全球製藥企業斥資數十億以擴大在美業務

4000 億美元併購談判崩盤：阿斯利康與百時美施貴寶合作宣告瓦解

环球市场播报

數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額

阿斯利康或將打破藥企十年併購策略，大手筆收購換取美國市場規模

环球市场播报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/AZNH/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1789494766449,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"09-15 13:52:46 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660498480","title":"第3次更新-阿斯利康因暫停volrustomig肺癌臨床試驗再遭挫折","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498480","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498480?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971447,"startTime":"0","endTime":"0","summary":"阿斯利康此前曾预测，volrustomig的峰值销售额将超过50亿美元。该公司表示，volrustomig与化疗联合使用时的安全性特征与各药物已知的安全性特征一致，未发现新的安全性信号。Volrustomig是一种双重检查点抑制剂双特异性抗体，旨在解除PD-1和CTLA-4这两条关键免疫通路的抑制，从而帮助免疫系统攻击肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","BK4585","LU0708994859.HKD","BK4568","LU2236285917.USD","LU0289739699.SGD","LU1267930573.SGD","LU2237443382.USD","LU0320765992.SGD","LU2237443622.USD","LU1829250122.USD","LU2237443895.HKD","IE00B3T34201.USD","LU2456880835.USD","LU0058720904.USD","LU0128525929.USD","LU2237443978.SGD","LU2417539215.USD","LU2237443465.HKD","AZN","LU0109394709.USD","LU0310800379.SGD","LU2089984988.USD","AZNH","BK4588","BK4007","LU0432979614.USD","LU2237443549.SGD","LU2468319806.SGD","LU0889565916.HKD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660248062?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0310800379.SGD","LU0889565916.HKD","LU0109394709.USD","AZNH","IE00B3T34201.USD","LU2417539215.USD","BK4007","BK4080","LU1267930573.SGD","LU0058720904.USD","III","LU2468319806.SGD","LU2089984988.USD","ADC","BK4588","LU0320765992.SGD","LU0029864427.USD","NETL","LU2462157665.USD","LU0289739699.SGD","LU1829250122.USD","LU2236285917.USD","LU0432979614.USD","LU0708994859.HKD","LU2237443622.USD","BK4231","LU2237443978.SGD","BK4568","LU2237443465.HKD","LU2237443895.HKD","LU0128525929.USD","LU2237443382.USD","AZN","LU2456880835.USD","LU2237443549.SGD","BK4585","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660147484","title":"阿斯利康終止一項肺癌三期臨床試驗，稱療效難達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660147484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660147484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:11","pubTimestamp":1786965064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BMED","LU0310800379.SGD","LU0058720904.USD","LU2237443549.SGD","LU2236285917.USD","LU0128525929.USD","AZNH","LU2089984988.USD","AZN","LU2237443978.SGD","LU2417539215.USD","IBBQ","LU0289739699.SGD","LU0432979614.USD","BK4588","LU2237443465.HKD","LU0889565916.HKD","BK4568","LU0320765992.SGD","BK4007","LU2237443622.USD","IBBJ","LU2237443895.HKD","PSYK","IE00B3T34201.USD","LU0029864427.USD","LU0708994859.HKD","MDTX","LU0109394709.USD","LU2462157665.USD","LU2237443382.USD","LU2456880835.USD","LU1267930573.SGD","LU1829250122.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660485253","title":"阿斯利康（AZN）再遇重大臨床研發挫折 宣佈停止肺癌治療藥物Volrustomig三期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2660485253","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660485253?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:52","pubTimestamp":1786956744,"startTime":"0","endTime":"0","summary":"研究结果显示，与现有的标准治疗方案相比，Volrustomig联合化疗未能显著提升晚期肺癌患者的生存率。值得注意的是，这也是阿斯利康在过去一个月内遭遇的第二次重大临床研发挫折。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU2237443382.USD","AZN","BK4007","LU0320765992.SGD","LU2236285917.USD","LU1829250122.USD","LU0432979614.USD","LU0029864427.USD","AZNH","LU0058720904.USD","LU1267930573.SGD","LU0289739699.SGD","LU2237443549.SGD","LU0708994859.HKD","LU2462157665.USD","LU2468319806.SGD","LU2237443622.USD","LU2237443895.HKD","LU2456880835.USD","LU2089984988.USD","LU2237443465.HKD","LU2417539215.USD","IE00B3T34201.USD","LU0109394709.USD","LU0889565916.HKD","BK4585","LU0128525929.USD","BK4588","LU0310800379.SGD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660362485","title":"阿斯利康（AZN）與日本第一三共聯合宣佈重磅抗體偶聯藥物Enhertu®三期臨床取得重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2660362485","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660362485?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:41","pubTimestamp":1786956109,"startTime":"0","endTime":"0","summary":"金吾财讯 | 跨国制药巨头阿斯利康 与日本第一三共联合宣布，其合作开发的重磅抗体偶联药物Enhertu在代号为“DESTINY-Lung04”的全球三期临床试验中取得积极成果。这是全球首个且唯一在HER2突变型非小细胞肺癌一线治疗中战胜标准疗法的HER2靶向药物。据悉，HER2突变型非小细胞肺癌约占非小细胞肺癌患者的2%至4%，常见于较年轻且无吸烟史的女性患者，侵袭性强且易发生脑转移。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU2417539215.USD","LU2468319806.SGD","LU2089984988.USD","LU2462157665.USD","LU2237443622.USD","LU1829250122.USD","BK4007","LU2237443978.SGD","LU1267930573.SGD","LU0432979614.USD","AZN","LU0058720904.USD","AZNH","LU0310800379.SGD","LU0029864427.USD","LU0128525929.USD","LU0109394709.USD","LU0320765992.SGD","LU0708994859.HKD","LU2237443895.HKD","BK4585","LU2236285917.USD","LU2456880835.USD","LU0289739699.SGD","BK4588","LU0889565916.HKD","LU2237443465.HKD","LU2237443382.USD","IE00B3T34201.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660334481","title":"泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2660334481","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660334481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:21","pubTimestamp":1786954860,"startTime":"0","endTime":"0","summary":"特泽利尤单抗的上市，为慢性鼻窦炎伴鼻息肉患者带来了新的治疗选择，有望帮助他们实现长期疾病控制，改善生活质量。携双适应症在华上市，特泽利尤单抗有望充分释放上游炎症通路靶点的临床价值，进一步完善我们在哮喘领域从轻中度到重度的全病程疾病管理布局，加速哮喘治疗迈向'临床治愈'愿景，同时满足广大慢性鼻窦炎伴鼻息肉患者的未尽之需。其中，高达10%的哮喘患者为重度哮喘22,23。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0889565916.HKD","BK4007","LU2462157665.USD","LU0320765992.SGD","LU2237443465.HKD","BK4568","IE00B3T34201.USD","ENTL","LU0289739699.SGD","AZNH","LU0128525929.USD","AZN","LU1829250122.USD","LU2456880835.USD","LU2237443622.USD","LU2237443978.SGD","LU2236285917.USD","LU0109394709.USD","LU0310800379.SGD","IPOS","LU0708994859.HKD","LU2237443895.HKD","LU1267930573.SGD","BK4585","BK4588","LU2089984988.USD","LU2468319806.SGD","LU0029864427.USD","LU0058720904.USD","LU2237443382.USD","LU2237443549.SGD","LU0432979614.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660072601","title":"阿斯利康(AZN.US)宣佈終止其實驗性藥物volrustomig的臨床試驗，此前數據顯示，該藥物似乎無法在肺癌治療方面","url":"https://stock-news.laohu8.com/highlight/detail?id=2660072601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660072601?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:48","pubTimestamp":1786949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LU0320765992.SGD","LU2236285917.USD","LU0029864427.USD","LU0109394709.USD","LU0432979614.USD","LU2462157665.USD","LU2237443382.USD","LU1829250122.USD","LU2237443549.SGD","BK4568","BMED","LU0289739699.SGD","LU2089984988.USD","LU0128525929.USD","LU2468319806.SGD","LU2237443978.SGD","LU2237443465.HKD","LU2237443895.HKD","LU2417539215.USD","IBBJ","LU0058720904.USD","LU1267930573.SGD","LU2456880835.USD","LU2237443622.USD","LU0889565916.HKD","LU0708994859.HKD","BK4007","BK4585","MDTX","IE00B3T34201.USD","IBBQ","AZN","AZNH","LU0310800379.SGD","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660074241","title":"阿斯利康宣佈泰適卓在華上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660074241","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660074241?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:24","pubTimestamp":1786947859,"startTime":"0","endTime":"0","summary":"阿斯利康宣布泰适卓在华上市","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843083635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843083635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2237443382.USD","LU0432979614.USD","LU2417539215.USD","LU2237443978.SGD","LU1267930573.SGD","LU2237443549.SGD","LU0708994859.HKD","LU2237443622.USD","LU2236285917.USD","LU0029864427.USD","LU2468319806.SGD","BK4007","IPOS","LU0320765992.SGD","LU0128525929.USD","AZNH","LU0058720904.USD","AZN","LU1829250122.USD","LU2237443895.HKD","LU0889565916.HKD","BK4585","LU2089984988.USD","BK4568","LU0109394709.USD","IE00B3T34201.USD","LU0310800379.SGD","LU2237443465.HKD","LU0289739699.SGD","LU2456880835.USD","LU2462157665.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660107356","title":"阿斯利康宣佈泰適卓正式在華上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660107356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660107356?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:19","pubTimestamp":1786947557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0310800379.SGD","IPOS","LU2237443978.SGD","LU0289739699.SGD","LU2089984988.USD","IE00B3T34201.USD","LU2417539215.USD","LU2237443382.USD","LU2462157665.USD","LU2236285917.USD","LU2237443622.USD","LU2237443549.SGD","LU2237443895.HKD","LU0109394709.USD","LU0320765992.SGD","AZN","LU0889565916.HKD","BK4588","LU0128525929.USD","LU2468319806.SGD","LU0058720904.USD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU0708994859.HKD","LU0029864427.USD","LU2456880835.USD","BK4568","BK4007","LU2237443465.HKD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416555","title":"據美國財經媒體Semafor：英國首相顧問曾就阿斯利康與百時美施貴寶的合併事宜致電阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416555","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416555?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 23:14","pubTimestamp":1786634047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0029864427.USD","LU0985481810.HKD","BK4532","LU1670711123.USD","LU2242646821.SGD","IE00B2B36J28.USD","AZN","BK4581","LU1883839398.USD","LU0109394709.USD","BK4588","BMY","LU1829250122.USD","IE00BFTCPJ56.SGD","AZNH","LU1093756168.USD","LU0289739699.SGD","LU0882574055.USD","LU2089984988.USD","LU2360032135.SGD","LU1868836757.USD","FTXH","LU1989771016.USD","IE00BFXG1179.USD","LU2236285917.USD","LU0456855351.SGD","LU2237443978.SGD","LU0128525929.USD","LU2242652126.USD","LU0096364046.USD","LU0237698245.USD","IE00B3T34201.USD","LU0708994859.HKD","LU1032466523.USD","LU2125154778.USD","LU2468319806.SGD","LU0267386448.USD","LU1261432733.SGD","LU2237443465.HKD","BK4559","IHE","LU2456880835.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","LU1430594728.SGD","LU1267930573.SGD","LU2125154935.USD","LU0321505439.SGD","LU0432979614.USD","LU2596442595.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165315","title":"市場消息：英國首相顧問就布里斯托爾併購案聯繫阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165315?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 23:13","pubTimestamp":1786633991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0029864427.USD","LU1267930573.SGD","LU0708994859.HKD","LU2462157665.USD","LU2468319806.SGD","LU0889565916.HKD","LU2237443978.SGD","LU0109394709.USD","LU2237443549.SGD","LU2236285917.USD","LU2237443622.USD","LU2237443382.USD","LU0058720904.USD","BK4007","AZNH","BK4585","LU0289739699.SGD","LU2089984988.USD","BK4568","LU0320765992.SGD","LU0432979614.USD","IE00B3T34201.USD","LU2417539215.USD","LU2237443895.HKD","LU2237443465.HKD","LU1829250122.USD","LU2456880835.USD","LU0310800379.SGD","LU0128525929.USD","AZN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659860121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZNH","LU0320765992.SGD","LU2456880835.USD","NETL","LU0128525929.USD","LU2237443549.SGD","LU0109394709.USD","IPOS","LU2237443978.SGD","BK4588","LU1829250122.USD","LU2237443382.USD","ADC","IE00B3T34201.USD","LU2468319806.SGD","LU2417539215.USD","LU0029864427.USD","LU0058720904.USD","LU2462157665.USD","AZN","BK4585","LU0432979614.USD","LU0889565916.HKD","BK4568","LU0708994859.HKD","BK4231","LU2236285917.USD","LU2237443895.HKD","LU2237443622.USD","LU2237443465.HKD","LU0289739699.SGD","BK4007","BK4080","LU0310800379.SGD","LU1267930573.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659901270","title":"康方生物雙抗藥物獲批第三項適應證 此前擊敗百濟神州；阿斯利康加入口服減重藥「混戰」：4500人Ⅲ期臨床試驗只對標安慰劑｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2659901270","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659901270?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 01:22","pubTimestamp":1786555325,"startTime":"0","endTime":"0","summary":"资本眼一周行情上周（8月3日至8月7日），医药生物指数上涨4.63%，跑赢上证指数（周内上涨2.81%）1.82个百分点。创新药（BK1106）周内上涨8.66%；恒生医疗保健业指数（HSCICH）周内上涨8.09%；港股创新药ETF广发（513120）周内上涨8.83%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839529518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839529518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","IE00B5MMRT66.SGD","LU0708994859.HKD","LU2237443622.USD","BK4007","LU2488822045.USD","LU0348766576.USD","LU0289739699.SGD","LU0310800379.SGD","MEDX","09926","ONC","LU1770034418.SGD","LU0432979614.USD","LU0348784397.USD","MDTX","LU0058720904.USD","LU2237443895.HKD","LNGR","LU0634319403.HKD","AZN","KURE","BK4585","06978","LU2237443382.USD","LU2089984988.USD","IE00BPRC5H50.USD","BK1583","688235","LU0307460666.USD","LU0417516738.SGD","PSYK","06160","LU0348783233.USD","BMED","LU2476274720.SGD","LU2462157665.USD","BK4588","LU2237443465.HKD","LU1251922891.USD","LU0128525929.USD","LU1969619763.USD","BK1161","IBBJ","IBBQ","BK0239","159992","LU0588546209.SGD","AZNH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658769979","title":"石藥創新(300765.SZ)：巨石生物已收到阿斯利康支付的3000萬美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658769979","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658769979?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:52","pubTimestamp":1786531939,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新(300765.SZ)发布公告，2026年7月1日，公司控股子公司巨石生物与阿斯利康签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。根据协议约定，巨石生物已于2026年8月12日收到阿斯利康支付的3000万美元首付款(实际到账金额须扣除银行手续费)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443549.SGD","LU0128525929.USD","LU2417539215.USD","LU0058720904.USD","LU2237443895.HKD","BK0226","LU2456880835.USD","BK4007","LU2237443465.HKD","AZNH","LU0310800379.SGD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","LU0889565916.HKD","LU0029864427.USD","BK4585","AZN","LU2237443622.USD","LU0708994859.HKD","LU2468319806.SGD","LU1267930573.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2089984988.USD","LU2237443382.USD","300765","LU2462157665.USD","LU1829250122.USD","LU2237443978.SGD","BK4568","LU0432979614.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658811976","title":"石藥創新：控股子公司收到阿斯利康3000萬美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658811976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658811976?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:06","pubTimestamp":1786529180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0289739699.SGD","LU2456880835.USD","LU2237443549.SGD","LU1829250122.USD","LU0029864427.USD","LU0128525929.USD","AZN","LU2468319806.SGD","LU2237443895.HKD","LU2237443465.HKD","LU2089984988.USD","LU1267930573.SGD","LU0320765992.SGD","LU2237443382.USD","LU2236285917.USD","LU0889565916.HKD","LU2462157665.USD","LU0109394709.USD","LU0708994859.HKD","LU2237443978.SGD","LU2237443622.USD","AZNH","BK4007","LU0310800379.SGD","LU0432979614.USD","BK4585","BK4568","LU2417539215.USD","LU0058720904.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976102","title":"優赫得聯合帕妥珠單抗在華獲批HER2陽性轉移性乳腺癌一線治療，成為十餘年來該領域首個獲批的創新ADC方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976102","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 17:15","pubTimestamp":1786526100,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗联合帕妥珠单抗组的PFS获益在各个预设亚组中均保持一致。在DESTINY-Breast09研究中，德曲妥珠单抗联合帕妥珠单抗治疗的中位无进展生存期超过三年，有望成为这一领域新的标准治疗，期待此治疗方案能使更多中国患者受益。此次获批标志着这一创新治疗方案进入了HER2阳性转移性乳腺癌更前线治疗阶段。此次获批标志着德曲妥珠单抗在中国迎来第八项适应症，其中五项为乳腺癌治疗领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5024779_ZH24779_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5024779_ZH24779_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443895.HKD","AZN","BK4080","LU2456880835.USD","LU2462157665.USD","LU0708994859.HKD","AZNH","LU0109394709.USD","LU0289739699.SGD","LU2468319806.SGD","BK4231","LU0128525929.USD","LU2089984988.USD","ADC","NETL","LU2236285917.USD","LU0310800379.SGD","LU1267930573.SGD","LU0320765992.SGD","LU0029864427.USD","LU2237443622.USD","BK4585","LU0432979614.USD","BK4568","LU2237443978.SGD","LU0889565916.HKD","LU2417539215.USD","LU1829250122.USD","LU0058720904.USD","BK4007","LU2237443549.SGD","LU2237443465.HKD","LU2237443382.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658591102","title":"數據簡報-全球製藥企業斥資數十億以擴大在美業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2658591102","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658591102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:59","pubTimestamp":1786463961,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美业务更新了第18段中关于百健生产工厂的数据路透8月11日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。这家制药公司宣布将投资 6.5 亿美元 ，以扩大其位于波多黎各洪科斯工厂的药品生产规模，此举预计将创造近 750 个就业岗位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S448167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","LU1699723380.USD","LU0006306889.USD","LU0994945656.USD","LU1093756325.SGD","OZEM","LU1280957306.USD","LU1069347547.HKD","LU2505996509.AUD","LU1804176565.USD","LU0070217475.USD","IE00BJLML261.HKD","VHT","LU1983299246.USD","LU0820562030.AUD","LU0128525929.USD","LU2129689431.USD","SG9999017495.SGD","LU0889566641.SGD","PAWZ","LU0124676726.USD","LU2462591350.SGD","SG9999013999.USD","LU2125154935.USD","LU2087621335.USD","SGXZ57979304.SGD","AZNH","BK4599","LU2347655073.USD","IE00BLSP4452.SGD","LU1261432733.SGD","LU1718418525.SGD","LU2023250330.USD","LU0106261372.USD","LU0861579265.USD","LU1732800096.USD","LLYX","LU2129689514.USD","LU0868494617.USD","IE00B19Z3581.USD","LU2089283258.USD","LU1914381329.SGD","LU0256863902.USD","LU0868494708.USD","LU1116320737.USD","BK4566","LU0385154629.USD","LU2168564222.USD","SG9999001440.SGD","LU2023250504.SGD","IE00B7KXQ091.USD","SG9999015986.USD","LU0289739699.SGD","SG9999014575.USD","LU0823434583.USD","LU1064131342.USD","BBH","LU0029864427.USD","LU1196500208.SGD","LU0786609619.USD","LU1121112475.USD","LU2491050154.USD","LU1366192091.USD","LU1066051811.HKD","LU0133085943.USD","LU1989772923.USD","LU1585245621.USD","LU1778281490.HKD","IE00BK4W5L77.USD","LU1066053197.SGD","LU0345770308.USD","LU0234570918.USD","LU0823416689.USD","LU0795875086.SGD","LU1894683348.USD","LU2430703251.USD","LU2264538146.SGD","LU0545039389.USD","LU1670710661.SGD","LU1868837136.USD","PPH","JDOC","LU0345770993.USD","LU0174119429.USD","LU2237443549.SGD","LU0211327993.USD","LU0965509101.SGD","LU0122379950.USD","LU2360032135.SGD","LU1829250122.USD","LU1974910355.USD","BIIB","BK4007","LU2417539215.USD","IE00BFXG1179.USD","LLII","LU2063271972.USD","LU0238689110.USD","IE000SO60NU8.SGD","BK4583","SG9999002232.USD","LU0162691827.USD","LU2896262040.SGD","LU0256863811.USD","LU2487616109.SGD","LU0070302665.USD","IE00BN8TJ469.HKD","LU0345769631.USD","IE00BBT3K403.USD","LU0466842654.USD","ABBV","LU0094547139.USD","BK4534","BK4516","LU1883839398.USD","IE00BVYPNV92.GBP","LU2552382132.HKD","LU2324357040.USD","LU1917777945.USD","LU0289961442.SGD","LU2505996681.GBP","LU0210528500.USD","IE00BN29S564.USD","LU1670711123.USD","LU1069344957.HKD","LU2271345857.HKD","LU0738911758.USD","LU0057025933.USD","LU0882574055.USD","LU1935042991.SGD","LU2360106947.USD","SG9999014880.SGD","BK4578","LU0553294199.USD","BK4532","LU2471134879.HKD","LU2361044865.SGD","LU0354030438.USD","LU2089984988.USD","SG9999015952.SGD","LU2023251221.USD","LU0965509010.AUD","WDNA","LU0426417589.USD","SG9999014914.USD","TMED","BK7067","IE00B775H168.HKD","LU2213496289.HKD","IE0004445015.USD","LLYZ","IE00BZ1G4Q59.USD","IBBQ","LU0545562505.USD","LU0114720955.EUR","IE00B3PB1722.GBP","IE00B19Z9Z06.USD","LU1670627923.USD","LU0097036916.USD","IE0002141913.USD","LU0795875169.SGD","LU0109394709.USD","LU2491049909.HKD","LU0072461881.USD","LU0208291251.USD","LU0820561909.HKD","FTXH","BK4504","IE00BJJMRX11.SGD","GDOC","LU0225284248.USD","LU0321505439.SGD","LU2361045086.USD","LU0942090050.USD","LU1221951129.SGD","LU1929549753.HKD","LU2108987350.USD","LU0345769128.USD","LU1035775433.USD","LU1043141123.HKD","LU0354030511.USD","LU2237443622.USD","LU0708995401.HKD","LU2491050071.SGD","LU0417517546.SGD","LU0109391861.USD","LU0237698245.USD","SG9999015978.USD","LU2357627491.SGD","IE00BWXC8680.SGD","SGXZ99366536.SGD","BIB","LU2125909593.SGD","IYH","LU0170899867.USD","LU1712237335.SGD","LU2430703178.SGD","LU2236285917.USD","LU0211328371.USD","LU2592432038.USD","LU1674673428.USD","IE00B894F039.SGD","LU0310800379.SGD","LU1674673691.USD","LU2111349929.HKD","LU2168564495.EUR","LU2433249047.HKD","LU2471134796.USD","LU0265550359.USD","LU2357305700.SGD","04332","LU0225771236.USD","LU0306807586.USD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU2403377893.USD","LU1232071149.USD","LU0456855351.SGD","LU2750360641.GBP","LU1894683264.USD","LLY","LU0211331839.USD","IE00BJT1NW94.SGD","LU1201861249.SGD","PJP","LU1571399168.USD","LU1323610961.USD","LU1941712348.USD","LU0225283273.USD","IE000M9KFDE8.USD","LU1093756168.USD","HRTS","IE000BZT7R73.USD","LU1814569148.SGD","JNJ","LU1023059063.AUD","LU1244550221.USD","LU0726765562.USD","SG9999014898.SGD","LU2361044949.HKD","LU0320765992.SGD","LU0058720904.USD","LU2168564149.EUR","LU0320765059.SGD","LU1003077747.HKD","IE00B1XK9C88.USD","IE0002270589.USD","LU0689626769.HKD","LU2089284900.SGD","LU1989771016.USD","SG9999002224.SGD","LU1720051017.SGD","LU1066051498.USD","ILDR","IE00B3T34201.USD","SG9999014906.USD","IE000WAW04H5.SGD","LU2028103732.USD","TRUH","IE00BLSP4239.USD","LU2168563687.JPY","LU2471134952.CNY","LU0965508806.USD","LU1670628061.USD","SG9999014567.USD","LU0640476718.USD","LU2087625088.SGD","CURE","LU1868836591.USD","SGXZ81514606.USD","LU1496350171.SGD","BK4533","LU1244550494.USD","AGNG","LU2168564065.EUR","LU2237438978.USD","BK7501","LU1057294990.SGD","LU1868837300.USD","LU0289739343.SGD","BK4568","LU2237443382.USD","SG9999018865.SGD","XLV","LU0471298694.HKD","IE000MB6IJN5.SGD","LU2746668461.USD","LU1506573853.SGD","GLAM","LU1074936037.SGD","FHLC","LU1979441026.SGD","BMED","LU0985481810.HKD","SG9999011175.SGD","IE00BKVL7J92.USD","LU1732799900.SGD","PFE","LU2602419157.SGD","LU0882574139.USD","LU0395794307.EUR","RXL","IE00BFSS8Q28.SGD","IBB","LU0267386448.USD","LU0708994859.HKD","IE00BKDWB100.SGD","LU0432979614.USD","LU2471134523.USD","IE00BVYPNW00.USD","LU0321505868.SGD","LU0943347566.SGD","BK4559","IE00B1BXHZ80.USD","IE0004445239.USD","LU2023250843.SGD","THNR","LU0683600562.USD","LU1548497426.USD","IE00BFSS7M15.SGD","LU1145028129.USD","BMY","LU0689472784.USD","LU1228905037.USD","LU0234572021.USD","LU1720051108.HKD","ELIS","LU0210536198.USD","LU0203345920.USD","LU1267930730.SGD","IE00BDGV0183.EUR","LU0965509283.SGD","LU1066051225.USD","LU0320765489.SGD","LU2237443465.HKD","LU1032466523.USD","LU0471298777.SGD","PBE","LU2237443895.HKD","LU2456880835.USD","IE00B4R5TH58.HKD","LU0158827781.USD","LU2211815571.USD","LU1670711040.USD","LU1244550577.SGD","IE0005OL40V9.USD","LU1037948897.HKD","CSL.AU","LU2430703095.HKD","LU2552382058.USD","MEDX","SG9999014542.SGD","GILD","LU1037948541.HKD","LU2125909247.SGD","IE00B19Z3B42.SGD","LU1032955483.USD","IXJ","IE00BGHQF631.EUR","SGXZ51526630.SGD","LU1923622614.USD","LU0130517989.USD","LU0353189763.USD","SG9999015945.SGD","LU0820561818.USD","IE00B19Z9P08.USD","LU2462157665.USD","LU1670710588.SGD","IE0000B7K699.USD","AZN","LU1116320901.HKD","IE00B4JS1V06.HKD","LU0320765646.SGD","SG9999015358.SGD","BK4588","LU0353189680.USD","LU0511384066.AUD","BK4550","IE0034235303.USD","LU2756315318.SGD","LU0306806265.USD","SG9999001176.SGD","LU2237443978.SGD","LU0964807845.USD","LU0203201768.USD","LU0265550946.USD","LU2265009873.SGD","SG9999015341.SGD","TBXU","LU1430594728.SGD","LU1061106388.HKD","LU1934455194.USD","SG9999003800.SGD","LU1059921491.USD","LU2746668974.SGD","LU0648001328.SGD","LU2756315664.SGD","LU0053666078.USD","LU1228905540.USD","SG9999014559.SGD","LU1934455277.USD","LU0859254822.USD","LU2552382215.SGD","LU1551013342.USD","LU0198837287.USD","LU1221951046.USD","MRK","IE0009355771.USD","IE00BK4W5M84.HKD","LU0477156953.USD","LU1934455863.HKD","BK4581","MHIP","LU1989772840.SGD","LU2242646821.SGD","SGXZ80539844.SGD","LU1941712264.USD","BK4592","SGXZ31699556.SGD","LU1127390331.HKD","LU2242652126.USD","LU2125154778.USD","IE00BFTCPJ56.SGD","LU1267930813.SGD","LU0203202063.USD","IE00B42XCP33.USD","IE00BKPKM429.USD","IE00BJJMRZ35.SGD","SG9999018857.SGD","LU0323591593.USD","LU2112291526.USD","LU0792757196.USD","LU2347655156.SGD","LU1551013425.SGD","SG9999001176.USD","LU2133065610.SGD","LU0061475181.USD","LU0203347892.USD","LU0787776722.HKD","AMGN","LU1868836914.USD","LU1267930490.SGD","LU1043141396.HKD","LU0661504455.SGD","LU2129689605.HKD","LU0980610538.SGD","LU1162221912.USD","LU0079474960.USD","LU1623119135.USD","GB00BDT5M118.USD","ELIL","LU2461242641.AUD","LU0949170772.SGD","LU0823434740.USD","LU0098860793.USD","IE00B2B36J28.USD","LU0096364046.USD","LU2106854487.HKD","MEDI","IHE","LU0158827948.USD","LU0426412945.USD","LU1035773651.USD","LU1629891620.HKD","IE00BSNM7G36.USD","BK7508","LU1988902786.USD","IE0001KFT4U8.USD","BK4139","LU2596442595.SGD","LU0069063385.USD","LU2750360997.AUD","LU1496350502.SGD","LU1839511570.USD","LU0672654240.SGD","LU2468319806.SGD","LU1291159041.SGD","LU0472753341.HKD","LU0130102774.USD","LU0266013472.USD","LU0985320562.USD","BK7511","BK4585","LU0912757837.SGD","LU0310799852.SGD","IE00BJJMRY28.SGD","LU1267930573.SGD","LU1868836757.USD","IE000F7OJYX1.SGD","LU0316494557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967620","title":"4000 億美元併購談判崩盤：阿斯利康與百時美施貴寶合作宣告瓦解","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967620","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658967620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:46","pubTimestamp":1786430760,"startTime":"0","endTime":"0","summary":"知情人士称，时至8月初，双方就一桩以换股为主的收购交易进入深度谈判：阿斯利康计划溢价收购百时美施贵宝。最快到2028年，该公司近半数营收将因药品专利到期面临承压风险知情人士透露，谈判当时已推进至深入阶段，阿斯利康与百时美施贵宝原本计划在8月中旬正式对外公布这笔并购。8月3日晚间，由董事长米歇尔德马雷牵头的阿斯利康董事会正式下令终止并购磋商。阿斯利康与百时美施贵宝均拒绝为本文置评。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-11/doc-inimxrni0655576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1267930573.SGD","LU1430594728.SGD","IE00B3T34201.USD","IHE","LU2417539215.USD","XMMO","LU2468319806.SGD","BK4588","LU1883839398.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1093756168.USD","LU1093756325.SGD","BK4581","LU1868836914.USD","LU1868837136.USD","LU2456880835.USD","IE0002141913.USD","LU2360032135.SGD","AZN","LU0237698245.USD","LU0882574055.USD","LU2237443978.SGD","LU2125154778.USD","LU0306806265.USD","LU1032466523.USD","LU1323610961.USD","LU2242652126.USD","LU0889565916.HKD","LU2237443382.USD","AZNH","LU2133065610.SGD","MYLD","LU1670710661.SGD","LU1074936037.SGD","LU1989771016.USD","LU0109394709.USD","CALF","BMY","LU1585245621.USD","BK4534","BK4532","FTXH","KCE","LU1261432733.SGD","LU2089984988.USD","LU0321505439.SGD","LU1670711040.USD","LU1868836591.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931998","title":"數據簡報-全球製藥企業斥資數十億以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931998?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:18","pubTimestamp":1786367928,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美国的市场份额修改发稿日期，补充百时美施贵宝的投资计划路透8月10日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。赛诺菲计划通过直接投资公司现有基地以及与其他国内制造商建立合作伙伴关系，扩大其在美国的生产能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T4470YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0057025933.USD","BK7501","LU0094547139.USD","IE00BKPKM429.USD","LU1066053197.SGD","ABBV","LU1069344957.HKD","LU0320765489.SGD","LU2471134952.CNY","LU2023250330.USD","LU2063271972.USD","LU0130102774.USD","LU0072461881.USD","LU0426417589.USD","LU0943347566.SGD","IE0034235303.USD","PBE","LU0109394709.USD","PFE","IE0002141913.USD","LU2089284900.SGD","LU0265550946.USD","PJP","SG9999015358.SGD","LU1057294990.SGD","LU1061106388.HKD","LU0320765646.SGD","SG9999014914.USD","LU2129689431.USD","SG9999002224.SGD","SGXZ80539844.SGD","LU2271345857.HKD","LU2347655156.SGD","BK4550","LU0795875169.SGD","LU2461242641.AUD","CURE","LU1037948541.HKD","LU0345769631.USD","BK4504","IE00BVYPNW00.USD","LU0109391861.USD","BIIB","LU1868836591.USD","LU1989771016.USD","BK4592","BK4585","LU0070217475.USD","IE0004445015.USD","LU0133085943.USD","LU0985320562.USD","IE00BVYPNV92.GBP","LU0266013472.USD","LU2133065610.SGD","SGXZ81514606.USD","BK4139","LU2237443382.USD","LU0553294199.USD","SG9999018865.SGD","GSK","IE00BLSP4239.USD","LU2213496289.HKD","LU2361044949.HKD","LU1093756325.SGD","LU1935042991.SGD","BIB","LU2430703095.HKD","SG9999015978.USD","LU1066051225.USD","LU0965508806.USD","LU0097036916.USD","LU2746668974.SGD","IE00BJJMRZ35.SGD","LU1814569148.SGD","LU0354030511.USD","LU0545562505.USD","LU2491050071.SGD","SG9999015945.SGD","LU1868837136.USD","LU0861579265.USD","LU1291159041.SGD","BK4599","IBBQ","LU2168564222.USD","IE0000B7K699.USD","LU1116320737.USD","LU2471134879.HKD","IE0002270589.USD","LU1670711123.USD","LU2552382132.HKD","GLAM","LU2471134523.USD","IE00B775H168.HKD","LU2168563687.JPY","SG9999014898.SGD","IE00B3PB1722.GBP","IE00BKVL7J92.USD","SG9999015952.SGD","JNJ","XLV","LU0029864427.USD","LU2468319806.SGD","IE00BBT3K403.USD","LU0256863902.USD","LU0211328371.USD","IE00BN8TJ469.HKD","BK4568","LU1712237335.SGD","LU2089283258.USD","IE000M9KFDE8.USD","LU2746668461.USD","LU2125909247.SGD","LU1506573853.SGD","LU0708995401.HKD","LU1261432733.SGD","AGNG","BK4566","LU1548497426.USD","LU2403377893.USD","AZN","SG9999014542.SGD","LU2125154778.USD","TMED","PAWZ","LU1196500208.SGD","LU0417517546.SGD","LU1221951129.SGD","SGXZ51526630.SGD","WDNA","LU0208291251.USD","LU1988902786.USD","LU1718418525.SGD","LU0820562030.AUD","LU0210536198.USD","LU1868836757.USD","LU0820561818.USD","LU2505996509.AUD","LU1551013342.USD","IE00BFSS8Q28.SGD","IE0001KFT4U8.USD","LU1032955483.USD","LU1145028129.USD","LU2750360641.GBP","SG9999014880.SGD","LU0882574139.USD","LU2456880835.USD","LU2129689514.USD","BK4581","SG9999011175.SGD","LU1127390331.HKD","IE00BGHQF631.EUR","LU0823416689.USD","LU0203201768.USD","ELIS","LU0070302665.USD","AZNH","IE00BDGV0183.EUR","IE00BJT1NW94.SGD","LU0545039389.USD","LU1043141396.HKD","IE00BN29S564.USD","LU0471298777.SGD","LU0395794307.EUR","LU1069347547.HKD","FHLC","LU0306807586.USD","LU2471134796.USD","LU1804176565.USD","LLY","MEDI","RXL","LU0661504455.SGD","LU1059921491.USD","LU0889565916.HKD","HRTS","SG9999002232.USD","IE00BJJMRX11.SGD","LU1883839398.USD","LU2462157665.USD","LU1670711040.USD","LU1914381329.SGD","IE00B19Z3B42.SGD","LU0689472784.USD","LU2552382215.SGD","LU2487616109.SGD","LU1037948897.HKD","LU0203202063.USD","LU2357305700.SGD","LU1941712264.USD","BK4533","LU2505996681.GBP","IE0004445239.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0385154629.USD","LU0868494617.USD","LU1267930813.SGD","IXJ","LU0949170772.SGD","LU2491049909.HKD","LU0211331839.USD","LU0289961442.SGD","LU2360106947.USD","LU2592432038.USD","SG9999018857.SGD","LU0942090050.USD","LU1571399168.USD","SG9999014567.USD","LU0640476718.USD","LU1732799900.SGD","AMGN","SG9999001176.USD","LU1093756168.USD","LU1670710661.SGD","LU1003077747.HKD","LU1043141123.HKD","LU1894683348.USD","NVOX","GB00BDT5M118.USD","IE00B3T34201.USD","LU1674673691.USD","CANC","LU2111349929.HKD","SG9999003800.SGD","LLYX","LU0511384066.AUD","BMY","LU1983299246.USD","LU1670628061.USD","IYH","LU2237443549.SGD","LU0306806265.USD","LU2462591350.SGD","LU2596442595.SGD","IE000F7OJYX1.SGD","IE000MB6IJN5.SGD","IE00BFSS7M15.SGD","LU1244550577.SGD","LU2168564065.EUR","BK4578","LU1228905540.USD","LU0265550359.USD","TBXU","LU1267930573.SGD","LU0320765059.SGD","LU0471298694.HKD","LU1244550221.USD","LU1974910355.USD","LU1674673428.USD","BK7067","LU0477156953.USD","IE000SO60NU8.SGD","LU0708994859.HKD","LU1670627923.USD","LU0823434740.USD","LU2125909593.SGD","LU2087621335.USD","LU0689626769.HKD","SG9999014906.USD","IE00B42XCP33.USD","LU2242646821.SGD","LU2347655073.USD","LU1064131342.USD","LU1162221912.USD","LU1267930730.SGD","LU0198837287.USD","IBB","LU0738911758.USD","LU1829250122.USD","LU0170899867.USD","LU0323591593.USD","LU0980610538.SGD","LU2087625088.SGD","LU0124676726.USD","LU0965509283.SGD","IE00B1XK9C88.USD","LU0345769128.USD","LU2756315318.SGD","BBH","LU1430594728.SGD","LU1232071149.USD","BK4534","LU1720051108.HKD","LU0353189763.USD","LU2023251221.USD","LU0211327993.USD","LU0321505439.SGD","LU1917777945.USD","LU0432979614.USD","BK4588","IE00B4JS1V06.HKD","LU1244550494.USD","IE0009355771.USD","IHE","LU1868836914.USD","LU1066051498.USD","LU2265009873.SGD","LU0006306889.USD","LU1778281490.HKD","IE00B1BXHZ80.USD","LU1201861249.SGD","LU0098860793.USD","LU0069063385.USD","LU0683600562.USD","LU2430703251.USD","LU2028103732.USD","LU0158827948.USD","LU0792757196.USD","LU0820561909.HKD","LU2360032135.SGD","LU0130517989.USD","LU0061475181.USD","LU0237698245.USD","LU0345770993.USD","LU0912757837.SGD","IE00BJJMRY28.SGD","LU2324357040.USD","BK7511","LU1670710588.SGD","LU0726765562.USD","LU1934455863.HKD","THNR","LU0787776722.HKD","CSL.AU","LU2361045086.USD","LU0466842654.USD","LU0162691827.USD","BK4583","LU2168564149.EUR","LU0672654240.SGD","LU0353189680.USD","LU2491050154.USD","LU0316494557.USD","SGXZ57979304.SGD","LU0786609619.USD","IE00BFXG1179.USD","LU0994945656.USD","LU2264538146.SGD","LU1066051811.HKD","LU1989772840.SGD","LU1032466523.USD","LU2430703178.SGD","SG9999001440.SGD","SG9999015341.SGD","LU2108987350.USD","LU2237443978.SGD","BK7508","LU1934455277.USD","IE00BK4W5L77.USD","LU2089984988.USD","SG9999001176.SGD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU0795875086.SGD","LU2112291526.USD","LU1366192091.USD","LU1035775433.USD","IE00B7KXQ091.USD","LU0345770308.USD","LU0310800379.SGD","LU0456855351.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU1894683264.USD","SG9999013999.USD","IE00B4R5TH58.HKD","FTXH","LU1720051017.SGD","LU1934455194.USD","GDOC","IE00BJLML261.HKD","LU2552382058.USD","LU2417539215.USD","LU2602419157.SGD","LU1929549753.HKD","LU2242652126.USD","LU1116320901.HKD","LU1989772923.USD","LU0210528500.USD","LU0859254822.USD","LU1699723380.USD","LU0310799852.SGD","GILD","LU0472753341.HKD","LU0965509101.SGD","SG9999014575.USD","LU1623119135.USD","LU0096364046.USD","SGXZ99366536.SGD","LU0868494708.USD","IE000WAW04H5.SGD","LU0079474960.USD","BMED","LU1228905037.USD","ELIL","LU1280957306.USD","LU0648001328.SGD","LU1221951046.USD","LU0965509010.AUD","LU2023250843.SGD","LU0267386448.USD","LU0354030438.USD","SG9999014559.SGD","LU2237443895.HKD","IE00BWXC8680.SGD","LU0203345920.USD","LU0225283273.USD","LU0321505868.SGD","LLYZ","LU1551013425.SGD","LU2106854487.HKD","LU1979441026.SGD","LLII","LU2357627491.SGD","IE00BLSP4452.SGD","LU0882574055.USD","LU2236285917.USD","LU2433249047.HKD","LU0426412945.USD","IE000BZT7R73.USD","LU0174119429.USD","IE00B2B36J28.USD","PPH","BK4532","LU2125154935.USD","GSKH","GSK.UK","LU0154236417.USD","LU0238689110.USD","ILDR","LU2168564495.EUR","LU0106261372.USD","LU0256863811.USD","LU2237438978.USD","BK4559","LU1629891620.HKD","IE00BK4W5M84.HKD","LU1941712348.USD","LU2237443465.HKD","LU1121112475.USD","LU1496350171.SGD","LU1496350502.SGD","LU0289739343.SGD","NVOH","IE00B894F039.SGD","LU0128525929.USD","LU1267930490.SGD","LU1023059063.AUD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4516","LU0225771236.USD","SGXZ31699556.SGD","04332","LU0122379950.USD","NVO","OZEM","LU2756315664.SGD","MHIP","LU2129689605.HKD","LU0964807845.USD","LU0234572021.USD","VHT","IE00B19Z9P08.USD","LU0114720955.EUR","SG9999017495.SGD","LU0289739699.SGD","TRUH","LU0823434583.USD","IE00BKDWB100.SGD","LU0058720904.USD","LU1839511570.USD","LU2896262040.SGD","MEDX","MRK","IE00B7SZLL34.SGD","LU2211815571.USD","LU0889566641.SGD","LU1923622614.USD","LU2361044865.SGD","LU1035773651.USD","LU0158827781.USD","LU0053666078.USD","IE0005OL40V9.USD","LU1323610961.USD","LU1732800096.USD","LU1868837300.USD","LU2237443622.USD","LU0203347892.USD","LU2023250504.SGD","LU0234570918.USD","LU0985481810.HKD","LU2750360997.AUD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657822796","title":"阿斯利康或將打破藥企十年併購策略，大手筆收購換取美國市場規模","url":"https://stock-news.laohu8.com/highlight/detail?id=2657822796","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657822796?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:24","pubTimestamp":1786011840,"startTime":"0","endTime":"0","summary":"依托百时美施贵宝深耕美国的业务，阿斯利康可一举获得美国市场规模，但代价是增长放缓，并承担巨大整合风险。本周，阿斯利康传出与美国竞争对手百时美施贵宝开展合并谈判，医药投资者大为震动。阿斯利康拒绝向 置评；百时美施贵宝并未回应采访请求。阿斯利康与百时美施贵宝在肿瘤赛道已形成直接竞争，意味着并购将迎来严苛的反垄断监管审查。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-06/doc-inimkskx2926837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0128525929.USD","LU0029864427.USD","LU2237443549.SGD","LU2237443622.USD","LU0310800379.SGD","LU2089984988.USD","BK4007","AZNH","LU0320765992.SGD","LU2237443465.HKD","LU0708994859.HKD","LU0289739699.SGD","IE00B3T34201.USD","LU2462157665.USD","LU2417539215.USD","LU0109394709.USD","AZN","LU2237443382.USD","BK4568","BK4588","LU1829250122.USD","LU2237443895.HKD","LU0058720904.USD","LU2237443978.SGD","LU0889565916.HKD","LU1267930573.SGD","LU2456880835.USD","LU2236285917.USD","LU2468319806.SGD","LU0432979614.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":163,"code":"91000000","status":"200"}]}}